Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Operating Leases (2021 - 2025)

Anaptysbio's Operating Leases history spans 5 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 14.74% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, down 14.74%, while the annual FY2025 figure was $12.0 million, 14.74% down from the prior year.
  • Operating Leases reached $12.0 million in Q4 2025 per ANAB's latest filing, down from $14.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $20.9 million in Q3 2021 to a low of $12.0 million in Q4 2025.
  • Average Operating Leases over 5 years is $17.0 million, with a median of $17.4 million recorded in 2023.
  • Peak YoY movement for Operating Leases: decreased 0.01% in 2023, then fell 22.73% in 2025.
  • A 5-year view of Operating Leases shows it stood at $19.4 million in 2021, then decreased by 8.42% to $17.8 million in 2022, then fell by 9.97% to $16.0 million in 2023, then fell by 12.0% to $14.1 million in 2024, then dropped by 14.74% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Operating Leases are $12.0 million (Q4 2025), $14.6 million (Q3 2025), and $13.1 million (Q2 2025).